Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation & Amortization (CF) (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Depreciation & Amortization (CF) for 11 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 7.79% to $2.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.8 million, a 5.11% decrease, with the full-year FY2025 number at $9.8 million, down 5.17% from a year prior.
  • Depreciation & Amortization (CF) was $2.4 million for Q4 2025 at Intellia Therapeutics, roughly flat from $2.4 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.6 million in Q2 2024 to a low of $1.6 million in Q1 2021.
  • A 5-year average of $2.2 million and a median of $2.2 million in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): grew 22.54% in 2024, then decreased 8.19% in 2025.
  • Intellia Therapeutics' Depreciation & Amortization (CF) stood at $1.9 million in 2021, then increased by 9.52% to $2.1 million in 2022, then grew by 19.77% to $2.5 million in 2023, then grew by 4.66% to $2.6 million in 2024, then decreased by 7.79% to $2.4 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Depreciation & Amortization (CF) are $2.4 million (Q4 2025), $2.4 million (Q3 2025), and $2.5 million (Q2 2025).